Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
bluebird bio
bluebird bio
Activities:
Research & Development
X
LinkedIn
Trending Articles
Counteracting counterfeits in the pharmaceutical supply chain
Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
Naobios successfully optimises Sumagen's HIV vaccine for industrial production
Naobios will now focus on developing processes for the cGMP manufacture of Sumagen's HIV-1 vaccine candidate
Enzene launches EnzeneX 2.0 technology for biologics at CPHI Milan 2024
New platform enables uninterrupted processing and significant cost reductions
New Berry bottle complements preservative-free eye treatment dispensing
Easy-squeeze ophthalmic bottle designed for use with Aptar Pharma’s dispenser
Domino makes it easier than ever for pharmaceutical manufacturers to explore individual dose serialisation
New enhancements to the K600G printing solution streamline integration and usability
Upcoming event
CPhI India
26–28 November 2024 | Online Conference & Networking | Delhi, India
See all
Related Content
Manufacturing
Minaris to manufacture Bluebird Bio therapy for CALD
Early Cerebral Adrenoleukodystrophy is a life-threatening progressive neurodegenerative disease
Ingredients
Refined commercial production spec gets gene therapy EMA go-ahead
US-based Bluebird Bio is working with German apceth Biopharma for commercial manufacturing of its one-time thalassemia therapy that is approved in the EU, not the US
Regulatory
Apceth bullish on manufacturing deal with bluebird bio
The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval
Manufacturing
Bluebird bio opens lentiviral vector manufacturing facility
The US company’s first facility will produce clinical and commercial supplies of gene therapy vectors, with room for expansion
Pharmaceutical
Collaboration to develop gamma delta CAR T cell product candidates
bluebird bio and Scottish immunotherapy company TC BioPharm, announced a strategic collaboration and license agreement focused on gamma delta CAR T cells
Research & Development
Lonza and Bluebird Bio announce commercial manufacturing agreement
For Lenti-D and LentiGlobin therapies for severe genetic diseases and T cell-based immunotherapies for cancer
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now